Retrospective studies found that after treatment with gefitinib or erlotinib, lung cancer patients with EGFR exon 19 deletions had a longer overall survival when compared with patients with EGFR L858R (Jackman et al, 2006; Riely et al, 2006). This evidence concerns the gene EGFR and lung cancer.